Analysis of SARS-CoV-2 Ig seroprevalence in Northern Ireland.

Michelle K Greene¹, Peter Smyth¹, Andrew English^{2,3}, Joseph McLaughlin², Magda Bucholc⁴,

Janice Bailie⁵, Julie McCarroll⁵, Margaret McDonnell⁶, Alison Watt⁷, George Barnes⁸, Mark

Lynch⁹, Kevan Duffin¹⁰, Gerard Duffy¹¹, Claire Lewis¹², Jacqueline A James^{1,12,13}, Tom Ford¹⁴,

Maurice O'Kane⁹, Taranjit Singh Rai², Anthony J Bjourson², Christopher Cardwell¹⁵, J Stuart

1

Elborn¹⁶, David S Gibson², Christopher J Scott^{1*}

¹The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK

² Personalised Medicine Centre, School of Medicine, Ulster University, Londonderry, UK

³ School of Health and Life Sciences, Teeside University, Middlesbrough, UK

⁴ Intelligent Systems Research Centre, School of Computing, Engineering & Intelligent Systems,

Ulster University, Londonderry, UK

⁵HSC R&D Division, Public Health Agency, Belfast, UK

⁶Department of Clinical Biochemistry, Belfast Health and Social Care Trust, Belfast, UK

⁷ Regional Virology Laboratory, Belfast Health and Social Care Trust, Belfast, UK

⁸Department of Clinical Biochemistry, South-Eastern Health and Social Care Trust, Dundonald,

UK

⁹Department of Clinical Biochemistry, Altnagelvin Hospital, Western Health and Social Care

Trust, Londonderry, UK

¹⁰Department of Clinical Biochemistry, Southern Health and Social Care Trust, Portadown, UK

¹¹Department of Clinical Biochemistry, Northern Health and Social Care Trust, Antrim, UK

¹²The Northern Ireland Biobank, Queen's University Belfast, Belfast, UK

13 Ragions a le Malegurlane Diagnostia Service e Bertinet Hallowan de Sociali Garre Useust guste tastal blectice.

¹⁴ Bacteriology Branch, Veterinary Sciences Division, AFBI, Belfast, UK

¹⁵Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's

University Belfast, Belfast, UK

¹⁶Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast,

UK

*Corresponding Author - Christopher J. Scott - Patrick G Johnston Centre for Cancer Research,

School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast BT9

7AE, U.K.; Email: c.scott@qub.ac.uk; Telephone: +44 (0)28 9097 2350

Abstract

Background: With the impact of SARS-CoV-2 upon public health directly and

socioeconomically, further information was required to inform policy decisions designed to

limit virus spread. This study sought to contribute to serosurveillance work within Northern

Ireland to track SARS-CoV-2 progression and guide health strategy.

Methods: Sera/plasma samples from clinical biochemistry laboratories were analysed for anti-

SARS-CoV-2 immunoglobulins (Ig). Samples were assessed using an Elecsys anti-SARS-CoV-2

or anti-SARS-CoV-2 S ECLIA (Roche) on an automated Cobas-e-analyser. Samples were also

assessed via ELISA (Euroimmun). A subset of samples assessed via Roche Elecsys anti-SARS-

CoV-2 IgG assay were subsequently analysed in an ACE2 pseudoneutralisation assay using a

V-PLEX SARS-CoV-2 Panel 7 for IgG and ACE2 by MesoScale Diagnostics Inc.

Results: Across three testing rounds (June-July 2020, November-December 2020 and June-

July 2021 (rounds 1-3 respectively)), 4844 residual sera/plasma specimens were assayed for

SARS-CoV-2 Ig. Seropositivity rates increased across the study, peaking at 11.6% during round

3. Varying trends in SARS-CoV-2 seropositivity were noted based on demographic factors. For

instance, highest rates of seropositivity shifted from older to younger demographics across

the study period. In round 3, alpha (B.1.1.7) variant neutralising antibodies were most

frequently detected across age groups, with median concentration of anti-spike protein

antibodies elevated in 50-69 year olds and anti-S1 RBD antibodies elevated in over 70s,

3

relative to other age groups.

Conclusions: With seropositivity rates of <15% across the assessment period, it can be concluded that the significant proportion of the Northern Ireland population had not yet naturally contracted the virus by mid-2021.

4

Keywords

SARS-CoV-2; seroprevalence; public health policy; seropositivity; demographics

Introduction

Since the first reports of SARS-CoV-2, countless individuals have contracted the disease

worldwide leading to significant mortality, morbidity and socioeconomic implications. Efforts

to control SARS-CoV-2 transmission led the UK government to impose nationwide lockdowns,

strict social distancing measures and widescale testing programmes to rapidly identify and

isolate infected individuals. Despite these restrictions, continued spread of SARS-CoV-2

remained a challenge, highlighting the need for ongoing surveillance to track disease

epidemiology and guide public health policy moving forwards.

Numerous options exist for testing and monitoring of SARS-CoV-2, including the reverse

transcription polymerase chain reaction (RT-PCR) that has formed the gold standard

diagnostic approach to date.¹⁻³ This highly sensitive technique facilitates the molecular

detection of viral RNA that is typically collected via nasopharyngeal swabs, although it is

prohibited by the need for significant laboratory infrastructure and longer turnaround times.

Moreover, RT-PCR is of limited use beyond the acute phase of SARS-CoV-2 infection so

prevalence rates may be grossly underestimated. Alternatively, serological assays enable the

detection of SARS-CoV-2-reactive antibodies in sera/plasma, which are released into the

circulation in the weeks following infection and often persist for many months thereafter.⁴⁻⁶

These assays therefore provide an indication of prior exposure to SARS-CoV-2 and are

particularly insightful for gathering information on asymptomatic infection in those who may

not have satisfied eligibility criteria for PCR screening, providing a more refined estimate of

SARS-CoV-2 prevalence. Many serological studies have been conducted worldwide⁷⁻¹² and

have informed planning in several contexts (e.g. vaccination scheduling in response to waning

immunity), highlighting the pivotal contribution of serosurveillance towards control and

containment of SARS-CoV-2.

For Northern Ireland in particular, estimates of SARS-CoV-2 seroprevalence have been largely

derived from the ongoing Coronavirus (COVID-19) Infection Survey, where sera are sampled

from randomly selected households across each of the jurisdictions within the UK. Here, we

employed an alternative sampling source to derive a further independent estimate of the

proportion of Northern Irish residents who contracted SARS-CoV-2 in the period to July 2021.

The Northern Ireland health system is divided into five Health and Social Care Trusts and

therefore to efficiently sample a broad spectrum of the population, residual sera/plasma

specimens were procured from clinical biochemistry laboratories within each of the five Trusts

and analysed for the presence of anti-SARS-CoV-2 immunoglobulins (Ig) using commercial

immunoassay kits in both hospital and academic settings. We report temporal and

demographic trends in Ig response, providing crucial insight into how seropositivity has

evolved over time and how it has been influenced by characteristics including age, gender and

place of residence.

Methods

Sample collection

Ethical approval for this study was obtained from the Northern Ireland Biobank. The Northern

Ireland Biobank has ethical approval from The Office of Research Ethics Committees Northern

Ireland (ORECNI REF 21/NI/0019) and can confer ethical approval for projects which have

received material from the bank. 13 Residual blood sera/plasma specimens (originally collected

and processed for other clinical purposes) were sourced from Clinical Biochemistry

laboratories within the various Health and Social Care Trusts across Northern Ireland,

comprising the Belfast, Northern, Southern, South Eastern and Western Health and Social Care

Trusts. Samples were acquired during three timeframes: June-July 2020, November-

December 2020 and June-July 2021.

Anti-SARS-CoV-2 IgG electrochemiluminescence immunoassay (ECLIA)

Sera/plasma samples were assayed using the Elecsys anti-SARS-CoV-2 or anti-SARS-CoV-2 S

ECLIA (Roche) on an automated Cobas e analyser in accordance with the manufacturer's

instructions.

Anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA)

Sera/plasma samples were assayed using the anti-SARS-CoV-2 IgG ELISA (Euroimmun) in

accordance with the manufacturer's instructions. Semiguantitative assessment of anti-SARS-

CoV-2 IgG was achieved by calculating the ratio of the extinction of the control or donor

sample over the extinction of the calibrator. Ratios were interpreted as follows: < 0.8 =

negative, ≥ 0.8 to < 1.1 = borderline and ≥ 1.1 = positive.

ACE2 pseudoneutralisation IgG assay

A subset of n=278 plasma samples collected in the June-July 2021 cohort with Roche Elecsys

anti-SARS-CoV-2 IgG assay data (n=219 S-antibody reactive samples; n=59 S-antibody negative

samples as controls) were subsequently analysed by an ACE2 pseudoneutralisation assay.

Receptor Binding Domain (RBD)-specific IgG and their neutralising capacity against SARS-CoV-

2 wild type and variants B.1.1.7 (Alpha), B.1.351 (Beta) and P.1 (Gamma) were measured using

the V-PLEX SARS-CoV-2 Panel 7 for IgG and ACE2 by MesoScale Diagnostics Inc. (MSD, USA) according to the manufacturer's instructions and expressed as neutralising antibody concentration in µg/ml. Briefly, the assay uses spot multiplexing of 9 viral antigens within each plate well. For the ACE2 neutralisation assay, the ability of antibodies to block the binding of ACE2 to its cognate ligands was measured. Antibodies in plasma samples (diluted 1:10) that block the RBD antigen interaction with ACE2 on the spots were analysed, and a recombinant human ACE2 conjugated with MSD SULFO-TAG™ was used for detection. All plates were analysed on a MESO QuickPlex SQ 120 electrochemiluminescence reader to measure the light emitted from the SULFO-TAG™. Results for the MSD assays are reported in µg/ml derived from back fitting the measured signals for samples to a calibration curve generated for each plate. For the 7-point calibration curve, a 4-fold serial dilution was used with two replicates at each calibrator level and an additional zero calibrator blank. By correcting for dilution, the final antibody concentrations in undiluted samples were obtained. Detailed information on antigens, control samples and ACE2 calibrator reagent, including concentrations in µg/ml, are presented in the kit inserts provided by MSD (ACE2 cat no. K15440U). Cut off values supplied by the manufacturer of 0.762 µg/ml and 0.533 µg/ml were used to determine participant reactivity to SARS-CoV-2 S1 RBD and SARS-CoV-2 spike, respectively.

Data analysis

Crude and standardised apparent proportions with anti-SARS-CoV-2 Ig were determined along with 95% confidence intervals. Additionally, crude and standardised true proportions were determined adopting the Bayesian method used by Public Health England¹⁴, which accounted for the sensitivity of 71/100 (71%) and specificity of 777/786 (98.9%) of the test. Crude true proportion was also determined using the Rogan-Gladen method¹⁵ to account for test

sensitivity and specificity and gave similar results (analysis not shown). GraphPad Prism software (version 9.1.1) was used to plot data. Variables including age, gender, Health and Social Care Trust and postcode area were analysed using descriptive statistics. Frequencies and percentages were calculated for categorical variables and median and inter-quartile range for continuous variables. The chi-squared test of independence was used to test whether the proportion of individuals with neutralising antibodies for spike and anti-RBD was similar across four age groups. Neutralising antibody concentrations in each age group, for wild type, alpha, beta, and gamma variants of spike and anti-RBD, were further compared using Kruskal-Wallis test (comparison between > 2 groups) and Wilcoxon test (pairwise-comparison between groups) with the Benjamini and Hochberg multiple comparisons test adjustment. The Shapiro-Wilk test was used to determine if the neutralising antibody concentration data significantly deviated from a normal distribution. The 'outcode' data, a partial UK postcode constituting the postcode area and the postcode district, available with each participant sample, was used to generate geographic maps of % reactivity and participant numbers. Outcode boundary shapes, the total number of individuals that tested positive for anti-SARS-CoV-2 IgG, and the total number of tests performed were used to calculate outcode-level % reactivity rates. Statistical analyses were performed using the R statistical software (version 3.6.3) in RStudio (version 1.2.5033).

Results

Across three testing rounds spanning June-July 2020, November-December 2020 and June-

July 2021 (rounds 1-3 respectively), a total of 4844 residual sera/plasma specimens were

assayed for SARS-CoV-2 Ig using a combination of commercial kits sourced from Euroimmun

and Roche. Initial analyses were conducted using the Euroimmun anti-SARS-CoV-2 ELISA with

the spike S1 domain as target antigen, whereas subsequent analyses employed the Roche

Elecsys assay to examine sample reactivity towards the nucleocapsid protein. This ensured

that seroprevalence estimates were confined to natural infection only and not confounded by

vaccinated individuals with induced antibody responses against the spike protein.

Our choice to sample at various timepoints enabled temporal assessment of antibody

responses at different phases of the pandemic. Round 1 studies were performed following the

first national lockdown that was enforced in March 2020 (post-lockdown 1), whereas rounds

2 and 3 coincided with the pre- and post-lockdown phases of the second national lockdown

imposed in December 2020 (pre- and post-lockdown 2, respectively). Of the 1108 samples

assayed during round 1, a total of 43 showed detectable levels of anti-SARS-CoV-2 Ig equating

to a seropositivity rate of 3.9% (95% CI 2.9%-5.4%) (Supplementary Table 1 and

Supplementary Table 2). This increased only marginally during round 2, where 5.2% (95% CI

4.0%-6.5%) of samples were seropositive for anti-SARS-CoV-2 Ig (64 of 1242). However, a more

pronounced increase was observed during round 3, where 11.6% (95% CI 10.4%-13.0%) of

10

samples were seropositive for anti-SARS-CoV-2 Ig (290 of 2494).

Variable antibody responses were also observed in different demographic cohorts segregated according to age, gender, Health and Social Care Trust or place of residence (Supplementary **Table 3**). Collective sera for the entire study were sampled from a wide age range of 0-100years, although the majority were from persons aged 50+ years with comparatively fewer from those <50 years during each testing round (Supplementary Table 3). Clear age-related differences in antibody responses were observed at various stages of the pandemic. For example, during round 1 of testing (post-lockdown 1), seropositivity rates were marginally lower in those aged 0 – 29 years at 2.7% compared to other age brackets (Figure 1). However, subsequent testing rounds revealed a shift in this trend as seropositivity rates became higher in the younger age brackets, peaking at 16.1% in 0 – 29 year olds during round 3 of testing (post-lockdown 2) (Figure 1).

The anti-lgG and anti-RBD lgG neutralising concentrations in round 3 sera/plasma showed age dependent increases for spike proteins (Figure 2). The majority of participants determined to be S-antibody reactive (by anti-SARS-CoV-2 IgG assay) had neutralising antibodies above the reactive cut-off for wild type (WT) spike (70.1%) and S1 RBD (73.4%) (Supplementary Table 4). Amongst the variants tested, higher proportions of the S-antibody reactive population showed neutralising antibody reactivity toward the alpha versions of S1 RBD (72.7%) and spike (64.4%) proteins. In addition, significant differences in the proportion of S-antibody reactive individuals with neutralising antibodies for WT (p < 0.001), and alpha (p < 0.001), beta (p = 0.001) and gamma (p < 0.001) variants of spike protein were found between age groups. We observed no significant age differences in the proportion of subjects with neutralising antibodies targeting WT (p = 0.22), and alpha (p = 0.26), beta (p = 0.06), and gamma (p = 0.08) variants of S1 RBD. However, significant differences in neutralising antibody concentrations

between age groups were observed both for the wild type (p < 0.001) and the alpha (p = 0.008)

variant of spike protein and the wild type (0.044) and the alpha (0.037) variant of S1 RBD. The

pairwise-comparison revealed statistically significant differences between: i) 0-29 and 50-69

age groups (p = 0.033), 0-29 and 70+ age groups (p = 0.033), 30-49 and 50-69 age groups (p =

0.004), and 30-49 and 70+ age groups (p = 0.004) for the wild type of spike protein; ii) 0-29

and 50-69 age groups (p = 0.047), 0-29 and 70+ age groups (p = 0.022), and 30-49 and 70+ age

groups (p = 0.045) for the alpha variant of spike protein; iii) 0-29 and 70+ age groups (p =

0.041) and 30-49 and 70+ age groups (p = 0.041) for the wild type of S1 RBD; and iv) 30-49 and

70+ age groups (p = 0.043) for the alpha variant of S1 RBD.

Variations in antibody response were also observed between genders as the pandemic

progressed, with males showing higher seropositivity rates than females during rounds 1

(4.2% vs. 3.4%) and 2 (5.4% vs. 5.0%) of testing, whereas this trend was reversed in round 3

(9.9% vs. 12.9%) (Figure 3). Of note, however, a much larger number of females were sampled

versus males during all three testing rounds (Supplementary Table 3).

In terms of Health and Social Care Trust, a comparable number of samples were assayed from

each of the Belfast, Northern, South Eastern, Southern and Western Trusts during all three

testing rounds (Supplementary Table 3). All Trusts recorded the highest seropositivity rates

during round 3 of testing (Figure 4A). For the Belfast, Northern and Western Trusts,

seropositivity increased with each sequential testing round. However, the Southern and South

Eastern Trusts showed an initial decline in seropositivity during round 2 versus round 1 of

12

testing, which was reversed during round 3.

Further analysis of the outcode-level % reactivity rates, showed outcode-related differences in antibody responses over the three rounds of study (Figure 4B-C). For round 1 of testing, overall seropositivity rates were highest in BT65 (Legahory, Moyraverty, Tullygally, Drumgor, Monbrief), BT62 (Craigavon, Portadown, Tandragee, Clare, Scotch Street), and BT17 (West Belfast, North Lisburn) postcode areas at 100.0%, 22.2% and 15.4% respectively. However, the number of participants differ significantly between postcodes, with the number of samples assayed from BT65, BT62, and BT17 at 1, 27, and 13 respectively. During round 2, the highest seropositivity rate of 33.3% was recorded for BT10 (South Belfast) and BT70 (Dungannon, Ballygawley, Cappagh, Castlecaulfield, Donaghmore, Galbally, Garvaghy, Pomeroy, Rock, Seskilgreen) postcodes. Although the BT65 postal area showed an initial decline in seropositivity during round 2 versus round 1 of testing, round 3 revealed a shift in this trend, with BT65 having again one of the highest seropositivity rates (55.6%) in Northern Ireland. During round 3, the BT94 postcode area (Irvinestown, Ballinamallard, Brookeborough, Tempo, Maguiresbridge, Lisbellaw) reported the highest proportion of individuals that tested positive for anti-SARS-CoV-2 IgG. For the following postcodes, seropositivity increased with each sequential testing round: BT4 (East Belfast), BT7 (South Belfast), BT11 (West Belfast), BT24 (Ballynahinch, Drumaness, Saintfield), BT28 (Lisburn, Ballinderry Lower, Ballinderry Upper, Stoneyford), BT30 (Downpatrick, Ardglass, Ballyhornan, Ballykinler, Castleward, Clough, Crossgar, Kilclief, Killard, Killough, Killyleagh, Listooder, Loughinisland, Seaforde, Strangford, Toye), BT34 (Newry, Annalong, Ballymartin, Cabra, Hilltown, Kilcoo, Kilkeel, Mayobridge, Rathfriland, Rostrevor, Warrenpoint), BT37 (Newtownabbey), BT47 (Derry, Waterside, Claudy, Feeny, Dungiven, Eglinton, Park, New Buildings), BT49 (Limavady, Ballykelly), BT66 (Derryadd, Derrytrasna, Dollingstown, Donaghcloney, Lurgan, Waringstown), and BT82 (Strabane,

Artigarvan, Ballymagorry, Bready, Clady, Douglas Bridge, Dunamanagh, Sion Mills, Victoria Bridge).

Discussion

Following the emergence of SARS-CoV-2, it was rapidly acknowledged that surveillance

programs would require urgent implementation to monitor virus activity and inform policy for

many years ahead. In response, our study was initiated to gather information on the

seroprevalence of anti-SARS-CoV-2 Ig in Northern Ireland, which would provide an indication

of those with previous exposure to the virus. Residual sera from clinical biochemistry

laboratories were assayed at various timepoints throughout 2020-2021 using a combination

of anti-SARS-CoV-2 immunoassays against both the spike and nucleocapsid antigens. Our

analysis showed that seroprevalence rates increased as the pandemic progressed and were

also strongly influenced by demographics including age, gender and place of residence.

A limited number of studies have investigated SARS-CoV-2 seroprevalence in Northern Ireland

to date. These include the ongoing COVID-19 Infection Survey, which was initially piloted in

England and subsequently extended to other devolved UK nations including Northern Ireland

in September 2020. A subset of the study participants provide blood samples for antibody

testing, allowing seroprevalence rates to be closely tracked with updates published at regular

intervals. Data indicated that in November 2020, an estimated 3.3% (95% CI: 1.6-6.0%) of the

Northern Ireland population would have tested seropositive for anti-SARS-CoV-2 Ig, rising to

7.8% (95% CI: 3.5-14.4%) in December 2020. 16-17 In comparison, the same time period was

captured during round 2 of our study where seroprevalence was estimated at 5.2% (95% CI:

4.0-6.5%). These figures are surprisingly similar despite the notable difference in sourcing sera

for both studies; either from hospital-based clinical biochemistry laboratories in our case, or

from randomly selected private residential households throughout the general population for

the COVID-19 Infection Survey. In another UK-wide multicentre study conducted between

April to July 2020, a seroprevalence of 0.9% (95% CI: 0.2-3.3%) was reported in children (aged

2-15 years, N=215) of healthcare workers based in Belfast. 18 This timeframe coincided with

round 1 of our study, where 12.5% of samples within this age bracket tested positive for anti-

SARS-CoV-2 Ig, although the low numbers involved (N=8) limit the robustness of these

findings.

In the round 3 cohort, neutralising antibodies were most frequently detected to spike and S1

RBD of the alpha (B.1.1.7) variant across most age groups, which was the predominant strain

in the preceding winter and spring months of 2021. 19 Since no record of vaccination or prior

SARS-CoV-2 infection was available, a more thorough interpretation of neutralising antibody

persistence was not possible. However median concentration of neutralising antibodies

directed toward spike protein WT and alpha variants were elevated in the 50-69 year olds

relative to other age groups, whereas median concentrations of those directed against the S1

RBD WT and alpha variants were observed at higher levels in the over 70 year old group only.

Also alpha variant specific neutralising antibodies were more frequently detected in the under

30 age group against S1 RBD than spike. These findings need confirmation in larger sized age

groups with full vaccination and infection history, if high throughput ACE2

pseudoneutralisation assays are to be used to predict population protective immunity. The

same ACE2 pseudoneutralisation assay has indicated that previous infection removed any

negative influence of age or immune senescence on the level and quality of vaccine-induced

immune responses in care home staff and patients.²⁰ However the round 3 data provide initial

insight into age related variations in neutralising antibody diversity in response to likely variant

virus infection in the under 30s in particular, along with vaccination rollout prioritised to the

over 50s, in the months preceding sample collection.²¹

Beyond Northern Ireland, there are abundant reports of SARS-CoV-2 seroprevalence studies,

totalling 3924 in 140 countries as listed on the SeroTracker database²² as of December 12th

2022 that have formed the basis of many comprehensive systematic reviews and meta-

analyses.²³⁻²⁴ Significant diversity exists amongst these studies, with many focusing on defined

study populations such as healthcare personnel, 25 nursing home residents, 26 schoolchildren, 27

blood donors²⁸ or those with comorbidities²⁹ that limit the ability to draw meaningful

comparisons with our own data. However, similar to our sampling methodology, several

studies also make use of existing residual sera from healthcare settings.³⁰⁻³¹ For example, a

Scottish study between April and June 2020 reported a seroprevalence of 4.3% (95% CI: 4.2-

4.5%) in residual samples from those accessing primary care via general practice.³² This

timeframe approximately correlated with round 1 of our study, where a similar

seroprevalence of 3.9% (95% CI: 2.9-5.4%) was observed.

Our choice of a 'convenience' sampling approach may have led to biased estimates of

seroprevalence in our study. We identified residual sera from clinical biochemistry

laboratories across Northern Ireland as a feasible sampling source, given that the routine

processing of blood in this setting would facilitate access to sufficient sample numbers to

address the urgent need for seroprevalence insights. However, with sera acquired from those

accessing healthcare, it is possible that many of these individuals may have comorbidities that

placed them at higher risk of severe infection. Such individuals may have been more likely to

comply with preventive public health measures, potentially leading to a reduced incidence of

infection as already noted in several publications.³³⁻³⁴ Nonetheless, we observed comparable

trends to the ONS survey as discussed previously, where a more robust sampling strategy was

employed.

A further limitation of our work relates to the demographic profile of the study population,

which was not wholly representative of the Northern Ireland general population. Recent

census data indicates that males and females comprise 49% and 51% of the Northern Ireland

population, respectively. Gender misrepresentation was therefore apparent in our study,

since sera were acquired from a disproportionate number of females (N=2679) versus males

(N=2160). Moreover, the age demographic of our study cohort did not reflect the Northern

Ireland population at large, with 66.6% of samples acquired from persons of 50+ years despite

this age bracket only constituting 36.77% of the overall population.³⁵⁻³⁶ Although our

estimates were adjusted in line with the true age and gender distribution of the Northern

Ireland population, this may not fully mitigate sampling bias in our study. Our findings must

therefore be interpreted with caution, especially in light of accumulating evidence that

demographic characteristics can influence susceptibility to COVID-19.38-40

In conclusion, our findings highlight the evolving trajectory of SARS-CoV-2 in Northern Ireland,

with seropositivity rates of <15% at three distinct timepoints suggesting that a significant

proportion of the population had not yet naturally contracted the virus by mid-2021.

Moreover, we report varying trends in seropositivity based on demographic factors, including

age in particular where the highest rates were recorded in older generations in mid-2020

before a shift to younger generations in mid-2021. Despite sampling constraints, our study

fulfilled the critical need for seroprevalence data following the outbreak of SARS-CoV-2,

providing timely insights into virus transmission to inform planning and public health policy in Northern Ireland.

Declarations

Ethical approval and consent to participate: Ethical approval for this study was obtained from

the Northern Ireland Biobank. The Northern Ireland Biobank has ethical approval from The

Office of Research Ethics Committees Northern Ireland (ORECNI REF 21/NI/0019) and can

confer ethical approval for projects which have received material from the bank.¹⁴

Consent for publication: Not applicable

Data availability: The datasets used and/or analysed during the current study are available

from the corresponding author on reasonable request.

Conflict of interest: None to declare

Funding: This research did not receive any specific grant from funding agencies in the public,

commercial, or not-for-profit sectors

Author Contribution: JSE, TF, AJB, JMcC, JB, DSG and CJS contributed to conception and design

20

of the study. MKG, PS, AE, JMcL, MB, TSR, MMcD, AW, GB, ML, KD, GD, CL, JAJ and MOK

contributed to acquisition of data. MKG, PS, AE, MB, JMcL, CC, TSR, AJB, DSG and CJS

contributed to analysis and interpretation of data. MKG, PS, DSG, CC and CJS drafted the

article. All listed authors provided final approval of the version to be submitted.

Acknowledgements: Not applicable

References

1 D'Cruz RJ, Currier AW, and Sampson VB. Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). *Front Cell Dev Biol* 2020; **8**: 468.

2 Ravi N, Cortade DL, Ng E, Wang SX. Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape. *Biosens Bioelectron* 2020; **165**: 112454.

3 Kevadiya BD, Machhi J, Herskovitz J, Oleynikov MD, Blomberg WR, Bajwa N, et al. Diagnostics for SARS-CoV-2 infections. *Nat Mater* 2021; **20(5)**: 593-605.

4 Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. Humoral Responses and Serological Assays in SARS-CoV-2 Infections. *Front Immunol* 2020; **11**: 610688.

5 Van Caeseele P, Bailey D, Forgie SE, Dingle TC, Krajden M, COVID-19 Immunity Task Force. SARS-CoV-2 (COVID-19) serology: implications for clinical practice, laboratory medicine and public health. *CMAJ* 2020; **192(34)**: e973-e979.

6 Vogl T, Leviatan S, Segal E. SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population. *Cell Rep Med* 2021; **2(2)**: 100191.

7 Lai CC, Wang JH, Hsueh PR. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review. *Int J Infect Dis* 2020; **101**: 314-322.

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based

8 Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al

seroepidemiological study. Lancet 2020; 396(10250): 535-544.

9 Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al I. Seroprevalence

of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based

study. Lancet 2020; **396(10247)**: 313-319.

10 Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, et al. Seroprevalence of immunoglobulin M and G

antibodies against SARS-CoV-2 in China. Nat Med 2020; 26(8): 1193-1195.

11 Murhekar MV, Bhatnagar T, Selvaraju S, Saravanakumar V, Thangaraj JWV, Shah N, et al

SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the

second nationwide household serosurvey. Lancet Glob Health 2021; 9(3): e257-e266.

12 Stadlbauer D, Tan J, Jiang K, Hernandez MM, Fabre S, Amanat F, et al. Repeated cross-

sectional sero-monitoring of SARS-CoV-2 in New York City. Nature 2021; 590(7844): 146-150.

13 Lewis C, McQuaid S, Clark P, Murray P, McGuigan T, Greene C, et al. The Northern

Ireland Biobank: A Cancer Focused Repository of Science. Open Journal of Bioresources 2018;

5(0): p.9.

14 Public Health England. Serological Surveillance: Summary report 4. Published 12 May 2020,

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1010478/S0367 PHE Serological Surveillance Summary Report 4.pdf;
[accessed on 16 January 2023]

15 Messam LLMcV, Branscum AJ, Collins MT, Gardner IA. Frequentist and Bayesian approaches to prevalence estimation using examples from Johne's disease. *Anim Health Res Rev* 2008; **9(1)**: 1-23.

16 Office for National Statistics. Coronavirus (COVID-19) Infection Survey: antibody data for the UK, January 2021;

https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsa nddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/antibodydatafo rtheukjanuary2021

[accessed on 31 August 2022].

17 Office for National Statistics. Coronavirus (COVID-19) Infection Survey: characteristics of people testing positive for COVID-19 in England and antibody data for the UK: December 2020; https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsa nddiseases/articles/coronaviruscovid19infectionsinthecommunity/healthandsocialcare/conditionsa https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsa <a href="https://www.ons.go

18 Waterfield T, Watson C, Moore R, Ferris K, Tonry C, Watt A, et al. Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study. *Arch Dis Child* 2021; **106(7)**: 680-686.

19 UK Health Security Agency. SARS-CoV-2 variants of concern and variants under

investigation in England: Technical briefing 41. Published 6 May 2022;

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment

data/file/1073698/Technical-Briefing-41.pdf

[accessed on 12 December 2022]

20 Tut G, Lancaster T, Krutikov M, Sylla P, Bone D, Kaur N, et al. Profile of humoral and cellular

immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents

and staff within residential care homes (VIVALDI): an observational study. Lancet Healthy

Longev 2021; 2(9): e544-e553.

21 Department of Health & Social Care. UK COVID-19 vaccines delivery plan. Published 11

January 2021;

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment

data/file/951928/uk-covid-19-vaccines-delivery-plan-final.pdf

[accessed on 12 December 2022].

22 Arora RK, Joseph A, Van Wyk J, Rocco S, Atmaja A, May E, et al. SeroTracker: a global SARS-

CoV-2 seroprevalence dashboard. *Lancet Infect Dis* 2021; **21(4)**: e75-e76.

23 Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global seroprevalence of

SARS-CoV-2 antibodies: A systematic review and meta-analysis. PLoS One 2021; 16(6):

24

e0252617.

24 Chen X, Chen Z, Azman AS, Deng X, Sun R, Zhao Z, et al. Serological evidence of human

infection with SARS-CoV-2: a systematic review and meta-analysis. Lancet Glob Health 2021;

9(5): e598-e609.

25 Moscola J, Sembajwe G, Jarrett M, Farber B, Chang T, McGinn T et al. Prevalence of SARS-

CoV-2 Antibodies in Health Care Personnel in the New York City Area. JAMA 2020; **324(9)**: 893-

895.

26 Ladhani SN, Jeffery-Smith A, Patel M, Janarthanan R, Fok J, Crawley-Boevey E, et al. High

prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19: Prospective cohort

study, England. EClinicalMedicine 2020; 28: 100597.

27 Ulyte A, Radtke T, Abela IA, Haile SR, Berger C, Huber M et al. Clustering and longitudinal

change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland:

prospective cohort study of 55 schools. BMJ 2021; 372: n616.

28 Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al. Seroprevalence of

anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science 2021; 371(6524): 79-82.

29 Abdi B, Ndoadoumgue AL, Djebara S, Zafilaza K, Palich R, Marot S, et al. High SARS-CoV-2

seroprevalence in HIV patients originating from sub-Saharan Africa in the Ile-de-France area:

25

Seroprevalence of SARS-CoV-2 in HIV patients. J Infect 2022; **85(2)**: e33-e36.

30 Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ et al. Seroprevalence of

Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA

Intern Med 2020; 180(12): 1576-1586.

31 Bajema KL, Wiegand RE, Cuffe K, Patel SV, Iachan R, Lim T, et al. Estimated SARS-CoV-2

Seroprevalence in the US as of September 2020. JAMA Intern Med 2021; 181(4): 450-460.

32 Dickson E, Palmateer NE, Murray J, Robertson C, Waugh C, Wallace LA, et al. Enhanced

surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-

CoV-2 during the first wave of the epidemic. *Public Health* 2021; **190**: 132-134.

33 Gallaway MS, Rigler J, Robinson S, Herrick K, Livar E, Komatsu KK et al. Trends in COVID-19

Incidence After Implementation of Mitigation Measures - Arizona, January 22-August 7, 2020.

MMWR Morb Mortal Wkly Rep 2020; 69(40): 1460-1463.

34 Islam N, Sharp SJ, Chowell G, Shabnam S, Kawachi I, Lacey B et al Physical distancing

interventions and incidence of coronavirus disease 2019: natural experiment in 149 countries.

BMJ 2020; 370: m2743.

35 Northern Ireland Statistics and Research Agency. Census 2021 population and household

estimates for Northern Ireland: Statistical bulletin. Published 24 May 2022;

https://www.nisra.gov.uk/system/files/statistics/census-2021-population-and-household-

26

estimates-for-northern-ireland-statistical-bulletin-24-may-2022.pdf

[accessed on 31 August 2022].

36 Northern Ireland Statistics and Research Agency. Census 2021 population and household

estimates for Northern Ireland. Published 24 May 2022;

https://www.nisra.gov.uk/system/files/statistics/census-2021-population-and-household-

estimates-for-northern-ireland-tables-24-may-2022.xlsx

[accessed on 31 August 2022].

37 Davies NG, Klepac P, Liu Y, Prem K, Jit M, CMMID COVID-19 working group; Eggo RM. Age-

dependent effects in the transmission and control of COVID-19 epidemics. Nat Med 2020;

26(8): 1205-1211.

38 Kim H, Fox AM, Kim Y, Kim R, Bae G, Kang M. Is the male disadvantage real? Cross-national

variations in sex gaps in COVID-19 incidence and mortality. Glob Public Health 2021; 16(12):

1793-1803.

39 Li H, Wang S, Zhong F, Bao W, Li Y, Liu L, et al. Age-Dependent Risks of Incidence and

Mortality of COVID-19 in Hubei Province and Other Parts of China. Front Med 2020; 7: 190.

40 O'Brien J, Du KY, Peng C. Incidence, clinical features, and outcomes of COVID-19 in Canada:

27

impact of sex and age. J Ovarian Res 2020; 13(1): 137.

Figures




Figure 1. Age breakdown of SARS-CoV-2 Ig seroprevalence for each testing round. Data presented as

% of sera within each age bracket that tested positive for anti-SARS-CoV-2 Ig.






Figure 2. Neutralising IgG concentration of round 3 subpopulation. Neutralising antibody concentration (μ g/ml) for a subpopulation of n=278 round 3 samples split by age group for wild type (grey dots), alpha (red), beta (green) and gamma (blue) variants of (A) spike protein and (B) receptor binding domain (RBD) of the S1 portion of the spike protein. Central horizontal bar is median, error bars are inter-quartile range; dotted line indicates reactivity cut off concentrations for (A) spike = 0.533 $\mu g/ml$ and (B) S1 RBD = 0.726 $\mu g/ml$.




Figure 3. Gender breakdown of SARS-CoV-2 Ig seroprevalence for each testing round. Data presented as % of sera within each gender that tested positive for anti-SARS-CoV-2 Ig.




Figure 4. Geographical breakdown of SARS-CoV-2 Ig seroprevalence for each testing round. (A) Health and Social Care Trust breakdown of SARS-CoV-2 Ig seroprevalence for each testing round. Data presented as % of sera within each Trust that tested positive for anti-SARS-CoV-2 Ig. (B-C) Outcode maps of % reactivity and samples tested. Increased colour density indicates: (B) percentage of the population reactive by IgG immunoassay and (C) numbers of individuals tested, per outcode region for each sampling round (i-iii).